Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

Ever since microRNAs (miRNAs) were first recognized as an extensive gene family> 20
years ago, a broad community of researchers was drawn to investigate the universe of small …

Small RNAs regulate a wide variety of biological processes by repressing the expression of
target genes at the transcriptional and post-transcriptional levels. To achieve these …

RNA-based therapies, including RNA molecules as drugs and RNA-targeted small
molecules, offer unique opportunities to expand the range of therapeutic targets. Various …

Since their serendipitous discovery in nematodes, microRNAs (miRNAs) have emerged as
key regulators of biological processes in animals. These small RNAs form complex networks …

MicroRNAs (miRNAs) are∼ 22 nt RNAs that direct posttranscriptional repression of mRNA
targets in diverse eukaryotic lineages. In humans and other mammals, these small RNAs …

MicroRNAs (miRNAs) are short endogenously expressed RNAs that have the potential to
regulate the expression of any RNA. This potential has led to the publication of several …

RNA-targeted therapies represent a platform for drug discovery involving chemically
modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif …

Genomic rearrangements, encompassing mutational changes in the genome such as
insertions, deletions or inversions, are essential for genetic diversity. These rearrangements …

MicroRNAs (miRNAs) are critical regulators of gene expression. As miRNAs are frequently
deregulated in many human diseases, including cancer and immunological disorders, it is …